Navigation Links
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Date:6/7/2008

Data from five pivotal phase 3 studies presented at the American Diabetes

Association 68th Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications: metformin, thiazolidinediones, insulin and sulfonylureas.

"Almost half the patients with type 2 diabetes are not at the American Diabetes Association recommended HbA1c goal of less than 7 percent, so it's important to have new treatment options that are both effective and well tolerated to potentially address the large number of patients who aren't adequately controlled," said Richard Pratley, MD, director of the Diabetes & Metabolism Translational Medicine Unit at the University of Vermont College of Medicine. "These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral anti-diabetic treatments as well as insulin, increasing the range of treatment options for patients."

In the alogliptin monotherapy study, a significantly greater percentage of patients achieved HbA1c levels of less than or equal to 7 percent. Similar results were seen in the add-on to metformin, thiazolidinedione and sulfonylurea studies. Across all studies, patients achieved significant reductions in HbA1c, up to 0.80 percent, depending on the alogliptin dose and their treatment regimen. Greater HbA1c reductions were seen in patients with higher baseline HbA1c. Safety results showed that alogliptin was weight neutral and well tolerated in patients with type 2 diabetes, with an incidence of hypoglycemia similar to placebo.

"Alogliptin is another example of Takeda's commitment to advance the science of diabetes," said David Recker, M.D., senior vice president, Clinical Sciences, at Takeda. "The addition of alogliptin to the Takeda diabetes franchise would potentially enable us to address two of the core defects associated with type 2 diabetes, insulin deficiency and insulin resistance, ultimately helping patients improve their overall blood glucose control."

Alogliptin Phase 3 Study Results

In all five studies, at study end (week 26), mean change from baseline HbA1c levels were significantly greater, (P<.001), for both 12.5 mg and 25 mg alogliptin doses versus placebo, respectively:
-- alogliptin monotherapy: -0.56 percent, -0.59 percent, -0.02 percent

-- metformin add-on: -0.60 percent, -0.60 percent, -0.1 percent

-- thiazolidinediones add-on: -0.66 percent, -0.80 percent, -0.19 percent

-- insulin add-on: -0.63 percent, -0.71 percent, -0.13 percent

-- sulfonylurea add-on: -0.38 percent, -0.52 percent, +0.01 percent

A greater percentage of patients achieved HbA1c levels of less than or equal to 7 percent at both 12.5 mg and 25 mg alogliptin doses versus placebo, respectively, in the following studies:
-- alogliptin monotherapy: 47 percent (P=.001), 44 percent (P=.008), 23

percent

-- metformin add-on: 52 percent (P<.001), 44 percent (P<.001), 18 percent

-- sulfonylurea add-on: 30 percent (P=.057), 35 percent (P=.002), 18

percent

In all five studies, at study end, mean changes from baseline HbA1c levels were similar regardless of age, BMI or ethnicity.

Alogliptin was well-tolerated at all doses and in combination with other type 2 diabetes medications. Common adverse events were similar across groups in each study.

Alogliptin Phase 3 Study Design

Phase 3 studies were conducted in over 2,000 patients in 220 centers worldwide. All five phase 3 studies were randomized, double blind, placebo-controlled studies, designed to assess the efficacy and safety of alogliptin, alone or when added to another type 2 diabetes medication: metformin, pioglitazone, insulin or glyburide. The primary end point was change from baseline in HbA1c at week 26 (or last observation) in the intent-to-treat population. Alogliptin was studied at 12.5 mg and 25 mg, once daily, in all studies.

In all studies, except for the insulin add-on, mean baseline HbA1c was between 7.9 percent and 8.1 percent, and mean duration of type 2 diabetes was between six to eight years. In the insulin add-on, mean baseline HbA1c was 9.3 percent and mean duration of type 2 diabetes was 13 years. Mean age, in all studies, was between 53 and 57 years.

About Hemoglobin A1c (HbA1c)

HbA1c is a measure of an individual's average blood sugar over a three-month period. The ADA has recommended a target HbA1c level of <7 percent. ADA guidelines recommend clinical intervention for HbA1c >8 percent and to be considered for HbA1c between 7 and 8 percent.

About Alogliptin

Alogliptin, previously known by the development code SYR-322, is a selective DPP-4 inhibitor and is under investigation for the treatment of type 2 diabetes. Alogliptin was designed by Takeda to selectively inhibit DPP-4 and not other closely related proteins that are associated with other biologic activity. In in vitro studies, alogliptin has been shown to be 10,000-fold more selective for DPP-4 over other closely related proteins.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes that block the degradation of incretin hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretin hormones are normally released in the digestive tract in response to food, and mediate glucose-dependent insulin secretion, accounting for over 50 percent of insulin release. In type 2 diabetes, GLP-1 levels are decreased and the insulinotropic response to GIP is reduced, resulting in the incretin defect, which contributes to insulin deficiency and high blood sugar. Alogliptin has displayed a weight-neutral profile along with a risk of low blood sugar similar to placebo due to DPP-4 inhibitors' glucose-dependent mechanism of action.

Discovered by Takeda San Diego, Inc., alogliptin is being developed by Takeda Global Research & Development and is currently in phase 3 clinical studies.

Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Global Research & Development Center, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Takeda Global Research & Development Center, Inc. supports clinical and product development activity for Takeda commercial organizations. With a robust pipeline of compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology and other conditions, Takeda rapidly brings innovative products to market to improve patient health and enhance the practice of medicine. To learn more about the company, visit http://www.tgrd.com.

(Posters 444, 445, 446, 477, 478)


'/>"/>
SOURCE Takeda Global Research & Development
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
9. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):